Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis: pooled interim results for up to 3 years from the ASSURE study
Long-term results show seladelpar treatment improves outcomes in primary biliary cholangitis patients, indicating its potential as a therapeutic option.
Key Points
Seladelpar treatment demonstrates sustained efficacy in primary biliary cholangitis patients over 3 years.
The interim results highlight safety profiles consistent with prior trials, supporting ongoing use.
Phase 3 ASSURE trial involved patients with inadequate response to ursodeoxycholic acid.
Long-term data from the ASSURE study could influence treatment guidelines for primary biliary cholangitis.